

STATUS OF THE CLAIMS

1.-16. Cancelled.

17. (Currently Amended) A method of treating viral or bacterial infections, inflammatory diseases, or a tumor, said method comprising:

- (a) administering a pharmaceutical composition comprising consisting essentially of a pharmaceutically effective amount of isolated granzyme B as the only pharmaceutically active component to cells affected by said infection or inflammatory diseases or tumor cells, said target cells bearing Hsp70 on their surface;
- (b) allowing granzyme B to enter said cells via ~~ion channels formed by~~ said Hsp70 on the surface of said cells; and
- (c) allowing said cells to undergo apoptosis as a result of the enzymatic activity of granzyme B.

18-24. (Cancelled).

25. (Previously Amended) The method of claim 17, wherein granzyme B is present in the pharmaceutical composition in a final concentration of 1 μ g/ml to 500 μ g/ml.

26. (Previously Amended) The method of claim 17, wherein granzyme B is present in the pharmaceutical composition in a final concentration of 1ng/ml to 10 ng/ml.

27. (Previously Amended) The method of claim 26 wherein granzyme B is present in the pharmaceutical composition in a final concentration of about 6 ng/ml.

28. (Previously Presented) The method of claim 17, wherein the viral infection is an infection by HIV or Hepatitis virus.

29. (Currently amended) A method of treating viral or bacterial infections, inflammatory diseases or a tumor, said method comprising:

- (a) analyzing target cells of a patient for surface expression of Hsp70;
 - (b) administering a pharmaceutical composition comprising a pharmaceutically effective amount of isolated granzyme B as the only pharmaceutically active component to cells affected by said infection or inflammation or tumor cells, said cells bearing Hsp70 on their surface;
 - (c) allowing granzyme B to enter said cells via ion channels formed by Hsp70 on the cell surface; and
 - (d) allowing said cells to undergo apoptosis as a result of the enzymatic activity of granzyme B, wherein said cells affected by said infection or inflammation or tumor cells are analyzed for surface expression of Hsp70.
30. (Previously Presented) The method of claim 29, wherein granzyme B is present in the pharmaceutical composition in a final concentration of 1 μ g/ml to 500 μ g/ml.
31. (Previously Presented) The method of claim 29, wherein granzyme B is present in the pharmaceutical composition in a final concentration of 1ng/ml to 10 ng/ml.
32. (Previously Presented) The method of claim 31 wherein granzyme B is present in the pharmaceutical composition in a final concentration of about 6 ng/ml.
33. (Previously Presented) The method of claim 29, wherein the viral infection is an infection by HIV or Hepatitis virus.